Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Randomized, Open-label, International, Multicenter Study to Compare Efficacy of Standard Chemotherapy vs. Letrozole Plus Abemaciclib as Neoadjuvant Therapy in HR-positive/HER2-negative High/Intermediate Risk Breast Cancer Patients

Next Previous
Trial Profile

Phase II, Randomized, Open-label, International, Multicenter Study to Compare Efficacy of Standard Chemotherapy vs. Letrozole Plus Abemaciclib as Neoadjuvant Therapy in HR-positive/HER2-negative High/Intermediate Risk Breast Cancer Patients

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Letrozole (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Goserelin; Leuprorelin; Paclitaxel
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Early breast cancer; HER2 negative breast cancer
  • Focus Therapeutic Use
  • Acronyms CARABELA

Most Recent Events

  • 04 Jun 2024 Results exploring the predictive role of baseline (BL) Ki67 and Recurrence Score (RS) in tumor samples, and their changes during treatment., presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 24 May 2024 According to EXACT Sciences Corporation media release, company will present abstracts highlighting the breadth and depth of the companys screening and diagnostic portfolio at the American Society of Clinical Oncology Annual Meeting, taking place May 31 to June 4, 2024, in Chicago, Ill.
  • 23 May 2023 Planned primary completion date changed from 28 Feb 2023 to 9 Jun 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top